Month: May 2022

Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented positive preclinical data for TPST-1495 at AACR Presented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACRSOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update. “The team continued to execute well throughout the first quarter of this year, enabling us to present the first clinical data from a Tempest program at the ASCO Annual Meeting in June,” said Stephen R. Brady, chief executive officer of Tempest. “We...

BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the first quarter ended March 31, 2021, and provided a corporate update. “We continue rapidly with our progress across multiple developmental programs around novel asset creation using SeqLL’s tSMS® platform,” said Daniel Jones, CEO, President, and Co-Founder of SeqLL. “Our team is focused on developing improved genetic tools for researchers, so they can better understand and detect the molecular mechanisms of disease which are essential for the continued development of new breakthroughs...

DALLAS, May 13, 2022 (GLOBE NEWSWIRE) — Applied Blockchain, Inc. (Nasdaq: APLD) (“Applied Blockchain” or the “Company”) today reported financial results for the fiscal third quarter ended February 28, 2022 and provided an operational update. Recent Operational and Financial HighlightsOperationalized first Next-Gen co-located datacenter in Jamestown, North Dakota in February 2022 at 55 megawatts (“MW”) currently operating just over 80MW, with remaining 20MW to come online in the next few weeks Formed joint venture (“JV”) with Antpool, an affiliate of Bitmain, in January 2022 for up to 1.5 gigawatts (“GW”) initially of co-hosting infrastructure with Applied Blockchain owning 80% of the JV Completed an initial public offering (“IPO”) with uplisting to Nasdaq in April, raising approximate net proceeds of...

Revenue growth of 62% / Total Gross Margin 26.4% NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary unaudited financial results for the fiscal year ended December 31, 2021, prepared in accordance with U.S. GAAP. Due to additional time required to complete its year-end reporting process, the Company determined that it was unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, within the prescribed time period without unreasonable effort and expense. The Company filed a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission on April 28, 2022. The Company is working diligently and expeditiously to complete the financial review...

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2022. “As reported earlier this week, we have reached general alignment with the U.S. Food and Drug Administration (“FDA”) on key aspects of the proposed design of an additional clinical trial comparing oral sulopenem to Augmentin® (amoxicillin/clavulanate) for the treatment of uncomplicated urinary tract infection (“uUTI”) in adult women...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021. “In Q1 of 2022 we have continued the significant progress of late 2021, advancing and expanding our portfolio of differentiated therapeutic product candidates in diseases such as Alzheimer’s disease (AD), ALS, and schizophrenia,” said Gene Williams, ProMIS’ Chairman and CEO. “Our lead program PMN310 for Alzheimer’s continues rapid progress to an IND filing and clinical trials....

Total revenue was €23.9 mm in Q1 2022 (20% above Q1 2021), while net gaming revenue was €25.5 mm in the period, 24% above Q1 20211.Mexico revenue was €8.9 mm in Q1 2022 (55% above Q1 2021), while Mexico net gaming revenue was €10.0 mm in the period, 56% above Q1 2021.Spain revenue (and net gaming revenue) reached €13.2 mm in Q1 2022, above Q1 2021 (pre-regulation) levels.Net loss was €10.1 mm in Q1 2022 versus a €6.1 mm loss in Q1 2021.Strong available cash position of over $100 mm (€91 mm) as of March 31, 2022.Madrid, Spain and Tel Aviv, Israel, May 13, 2022 (GLOBE NEWSWIRE) – Codere Online (Nasdaq: CDRO / CDROW), a leading online gaming operator in Latin America, has released its financial results for the first quarter ended March 31, 2022. Below are the main financial and operating metrics of the period.  Quarter ended...

FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in the U.S. market in April for the topical treatment of acne vulgaris in patients nine years of age and older and EPSOLAY to launch in the second quarter for the treatment of inflammatory lesions of rosacea in adultsSol-Gel’s cash runway expected to extend through the end of 2023NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first...

— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer —  — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference call and live webcast at 8:00 a.m. ET today — DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments. “We are pleased...